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Introduction
Background
Multiple sclerosis (MS) is an immune-mediated 
chronic inflammatory disease of unclear aetiology 
which is characterized by demyelination and 
axonal damage [Compston and Coles, 2008]. 
Further, MS is the most frequent neurological dis-
ease leading to disability and early retirement in 
young adults. In the initial phase, MS often occurs 
as clinically isolated syndrome (CIS), for example, 
blurred vision by one-sided optic neuritis, together 
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Abstract
Background: Improved clinical effectiveness and therefore positive modification of multiple 
sclerosis (MS) with basic therapy can be achieved by long-term regular intake of drugs as 
prescribed but investigations have shown that a high percentage of patients do not take their 
medications as prescribed.
Objectives: We assessed the satisfaction and adherence of patients with MS with their current 
disease-modifying treatment under clinical practice conditions. We compared different facets 
of satisfaction as well as their internal relationship and identified predictors in an exploratory 
manner.
Methods: Therapy satisfaction in patients with relapsing–remitting multiple sclerosis (THEPA-
MS) was a noninterventional, prospective cross-sectional study performed throughout 
Germany in 2013 and 2014, and included patients with clinically isolated syndrome or 
relapsing–remitting MS. We applied a standardized approach to document satisfaction 
and adherence by patient-reported outcomes (Treatment Satisfaction Questionnaire for 
Medication) as well as by physician ratings.
Results: Of 3312 patients with a mean age of 43.7 years, 73.3% were women and the mean 
level of disability according to the Expanded Disability Status Scale was 2.29; 13.3% did 
not receive any medication at the time of documentation, 21.3% received interferon β1a 
intramuscularly, 20.7% had interferon β1a subcutaneously, 17.0% had interferon β1b 
subcutaneously and 23.7% had glatiramer acetate. Adherence rates varied between 60% 
(lifetime) and 96.5% (current medication). Differences between current medications were 
found for side effects and convenience scores but not for effectiveness, satisfaction and 
adherence. Higher global satisfaction and effectiveness were associated with fewer relapses, 
longer duration of medication, lower disability score and the absence of several side effects.
Conclusion: In a connected model of patient satisfaction, effectiveness, side effects, 
convenience and adherence, patients’ individual needs and concerns have to be addressed. 
Most differences were found with respect to side effects and convenience of treatment. 
Therefore, an improvement in these two domains seems to be the most promising proximate 
approach to elevate adherence levels.
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with disease signs manifest on magnetic resonance 
tomography. In about 85% of patients the relaps-
ing–remitting form (RRMS) manifests which is 
characterized by a pattern of clearly defined 
relapses that are divided by symptom-free periods 
[Compston and Coles, 2008]. If not treated, 
RRMS after about 10 years transitions into the 
secondary progressive form (SPMS), with increas-
ing disability. To date, MS cannot be cured. A 
number of disease-modifying treatments (DMTs) 
have been shown to reduce the number of relapses, 
to slow progression of disease and thus delay disa-
bility. The guidelines released by the German 
Neurological Society (DGN) issued in 2012 rec-
ommend as basic (first-line) treatment for CIS/
RRMS interferon (IFN) β1a or β1b preparations, 
glatiramer acetate (GA), and only with restrictions 
azathioprine (AZA) or immunoglobulins (IGs) 
intravenously. IFN and GA require yearlong intra-
muscular or subcutaneous injections (depending 
on the drug once daily or once weekly).
In a recent meta-analysis by Giovannoni and col-
leagues that analysed the data of 50 randomized 
studies and 19 observational studies in MS, mean 
discontinuation rates of 17–36% for such thera-
pies were noted [Giovannoni et  al. 2012]. The 
most frequent reasons were side effects and lack 
of efficacy. The meta-analysis identified flu-like 
symptoms (IFN) and reactions at the injection 
site (GA) as the most frequent side effects, in 
agreement with the prescribing information 
sheets. The incidence of side effects remained 
high in studies of more than 2 years’ duration and 
therapy discontinuations accumulated over time. 
In another study on therapy adherence in MS, as 
justification for therapy discontinuation, lack of 
efficacy was noted in 30–50% and side effects in 
up to 50% of patients [Kern et al. 2008]. In recent 
years, much research has been performed on the 
patient perspective and the importance of patient 
preference in the choice of treatments and patient 
adherence to prescribed MS therapy. A recent 
meta-analysis suggests that greater treatment sat-
isfaction is associated with improved persistence, 
and with lower regimen complexity or treatment 
burden [Barbosa et al. 2012].
Satisfaction is a determinant of adherence to 
treatment [Albrecht and Hoogstraten, 1998; Hirji 
et  al. 2013; Turk-Adawi et  al. 2013; Chrystyn 
et al. 2014; Wong et al. 2015]. Further, it affects 
health-related decisions, treatment-related behav-
iours and the impact of treatment outcomes 
[Lindhiem et al. 2014].
For chronic diseases such as MS, the regular intake 
or administration of drugs as prescribed by the 
treating physician, for example, high adherence to 
therapy, is a prerequisite for treatment success 
[Osterberg and Blaschke, 2005; Ho et al. 2009].
A number of investigations in various disease 
areas have shown that a high percentage of 
patients do not take their medications as pre-
scribed. Claxton and colleagues concluded based 
on a systematic review that not only patients with 
chronic diseases such as arterial hypertension or 
diabetes mellitus (which usually cause little incon-
venience or side effects) but also those with can-
cer have a compliance rate below 80% [Claxton 
et al. 2001].
With increasing treatment duration, adherence 
decreases [Vrijens et  al. 2008]. Underlying rea-
sons are complex, and as central factors missing 
understanding of the patients for the need of 
chronic therapy, but also side effects play an 
important role [Osterberg and Blaschke, 2005; 
Horne, 2006; Ho et al. 2009].
On the basis of a systematic literature search, 
Costello and colleagues listed the following as 
pivotal factors for low therapy adherence in 
patients with MS: forgetfulness, fear of the injec-
tion, missing efficacy as assessed by the patient, 
side effects, problems with complex treatment 
schemes, as well as fatigue [Costello et al. 2008].
With decreasing adherence, the relative risk of 
relapses increases [Steinberg et  al. 2010]. 
Improved clinical effectiveness and therefore pos-
itive modification of MS with basic therapy can 
be achieved by long-term regular intake of drugs 
as prescribed. Therapy satisfaction of patients is 
likely directly linked to adherence.
Objectives
With our study ‘Therapy satisfaction in patients 
with relapsing–remitting multiple sclerosis’ 
(THEPA-MS), we aimed to assess the satisfaction 
of patients with MS with their current DMT under 
clinical practice conditions. We undertook a stand-
ardized, broad approach to document satisfaction 
and adherence by patient-reported outcomes as 
well as by physician ratings beyond literature 
reviews. We intended to compare different facets 
of satisfaction and their internal relationship, and 
identify predictors of treatment-related satisfaction 
in an exploratory, data-driven manner.
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Further, we wanted to provide reference values 
for the Treatment Satisfaction Questionnaire for 
Medication (TSQM) from a large set of patients 
with CIS/RRMS being treated with first-line MS 
basic therapy as specified in the DGN guidelines 
(IFN of any type, GA, AZA, IGs) [DGN/KKNMS 
(Kompetenznetzwerk Multiple Sklerose), 2012].
Methods
Participants
THEPA-MS was a multicentre, open, prospec-
tive, noninterventional cross-sectional study. 
Patient data were obtained in 445 neurological 
practices at a single time point between August 
2013 and April 2014 in all parts of Germany. 
The ethics committee of the Medical Faculty of 
the Technical University of Dresden approved 
the study materials. All patients provided written 
informed consent prior to inclusion. Patients 
were eligible for documentation if they had a 
verified MS diagnosis according to the McDonald 
criteria and met the following criteria: age at 
least 18 years; CIS/RRMS; received MS first-
line therapy (interferon β1a or β1b intramuscu-
larly or subcutaneously; GA subcutaneously; 
AZA; IGs) as current treatment or were princi-
pally eligible for first-line treatment (irrespective 
of whether it was performed or not) and had 
received no escalation therapy in the past 
[Polman et al. 2005].
Measures
In an initial step, physicians were requested to fill 
out a questionnaire to describe their personal and 
centre characteristics. For every patient they doc-
umented sociodemographic data (age, sex, occu-
pational status, family status).
They also documented MS characteristics and 
therapy in detail [among others, date of diagnosis/
disease duration, current MS diagnosis, current 
Expanded Disability Status Scale (EDSS) score, 
number of relapses in the last year, presence of 
fatigue or depression, MS treatment duration and 
current MS basic therapy with treatment dura-
tion] [Kurtzke, 1983, 2000]. In addition, the fol-
lowing side effects and changes in laboratory 
parameters related to the current MS first-line 
therapy (within 3 months prior to the documenta-
tion date) were recorded: injection site reaction, 
pain, flu-like symptoms, headache, acute postin-
jection reaction, lymphadenopathy, increased 
fatigue, infection, elevated transaminases, neu-
tropenia, lymphocytopenia, leukopenia and 
thrombocytopenia. If no current MS therapy was 
administered, reasons for nontreatment or dis-
continuation of prior therapy were documented. 
Further, physicians rated therapy satisfaction and 
adherence.
The TSQM is an instrument for the assessment of 
patients’ satisfaction with their current medication 
[Atkinson et  al. 2004, 2005]. The questionnaire 
(version 1.4) consists of 14 questions. Besides 
global treatment satisfaction, satisfaction in the 
dimensions of side effects, efficacy and conveni-
ence are rated. Higher levels of satisfaction are 
expressed as higher TSQM scores. The TSQM 
has been validated in patients with various chronic 
diseases (such as migraine, arthritis, depression, 
asthma and hypertension) and showed high relia-
bility and validity despite the heterogeneity of 
patient groups [Atkinson et al. 2004].
In addition, four supplemental questions on 
patient satisfaction (developed for this study) 
were asked with respect to drug treatment and 
regularity of drug intake. Patients were asked to 
fill in answers to all questions themselves, but in 
the case of physical disability, they could accept 
help from other people.
Statistical analysis
All statistical comparisons were two tailed and a p 
value of less than 0.05 indicated statistical signifi-
cance. Continuous variables were checked for the 
assumption of data with normal distribution by 
the Shapiro–Wilk test. Non-Gaussian variables 
were log transformed before analyses. When no 
normal distribution could be obtained, only non-
parametric tests were applied. For AZA and IGs, 
only descriptive statistics were presented due to 
the limited number of patients receiving these 
medications and the restrictions of the DGN 
guidelines.
Exhaustive χ2 Automatic Interaction Detection 
(CHAID) analysis, a nonparametric method for 
analysing nominal, ordinal and continuous out-
comes with multiple Bonferroni adjusted χ2 tests, 
was used in (classification and) regression tree 
models (CRTs) with 10-fold cross validation and 
complete regrouping of predictor variables provid-
ing insights on the connection between a set of pre-
dictors and the respective outcome [Kass, 1980; 
Loh, 2014]. Age, sex, disease duration, EDSS 
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score, annual relapse rate, current DMT, number 
of medication changes, duration of medication 
intake, presence of adverse events or laboratory 
changes, current diagnosis of a major depressive 
episode (MDE) or disease-related fatigue, current 
family and occupational status were included in 
the analysis model as potential predicting factors 
for treatment satisfaction. To validate the results 
generated by the CRTs, analyses of variance 
(ANOVA) with medication as an independent var-
iable and analyses of covariance (ANCOVAs) 
including the same set of predictors were calcu-
lated. For effectiveness and global treatment satis-
faction (by TSQM), all DMTs were analysed 
in one approach whereas convenience and side 
effects were analysed for each DMT separately. 
Differences in metric variables between groups 
were assessed with (Bonferroni-adjusted) t tests or 
Mann–Whitney U tests in the case of non-Gauss-
ian distributions. A linear regression model was 
estimated with global satisfaction as dependent 
variable and the effectiveness, side effects and con-
venience as predictors. For correlations between 
physician ratings and TSQM scores, Kendall τ-b 
rank correlation coefficients were calculated.
We used IBM SPSS version 23.0 (IBM 
Corporation, Armonk, NY, USA) for all statisti-
cal computations.
Results
Patient characteristics
A total of 3312 evaluable patients with MS were 
documented by their attending physician. Mean 
age was 43.7 years (±11.3 standard deviation, 
SD) and 73.2% of patients were women. Nearly 
half of patients (45.5%) worked full time, 15.6% 
worked part time (7.9% as a result of MS) and 
17.0% of patients were permanently unable to 
work (16.3% as a result of MS). A total of 50.1% 
of patients were married and 20.7% lived with a 
partner. The vast majority of patients were diag-
nosed with RRMS (96.5%), followed by 3.5% 
with CIS. Looking at the number of relapses 
within the past 12 months prior to study entry, 
62.1% of the patients were relapse free, 27.7% 
had one relapse, 7.9% had two relapses and 1.9% 
were affected by three or more relapses. The 
mean duration of disease was 9.04 years (±7.08 
SD) and the level of disability by EDSS was esti-
mated between 2.29 (mean ± 1.55 SD) and 2.0 
(median). On average, patients were 34.1 ± 10.4 
years old at first occurrence of MS symptoms, 
and 35.6 ± 10.5 years at diagnosis of MS. Of all 
3312 patients, 441 (13.3%) did not receive any 
medication at the time of documentation, 704 
(21.3%) patients received IFN β1a intramuscu-
larly, 687 (20.7%) had IFN β1a subcutaneously, 
564 (17.0%) had IFN β1b subcutaneously, 785 
(23.7%) had GA and only a small number were 
prescribed AZA (n = 37, 1.1%) and IG (n = 6, 
0.2%). For further analyses, 3269 patients were 
eligible.
A total of 270 patients (8.2%) had only been 
treated in the past but were not currently receiving 
treatment. Average duration of the MS basic ther-
apy last prescribed was 2.7 ± 3.1 years. The deci-
sion to terminate the therapy had primarily been 
made by the patients (65.6%). In total, 47.8% of 
patients terminated therapy on account of side 
effects; 191 patients (5.8%) had never received 
MS treatment, and of those, the decision against 
therapy was essentially taken by the patient in 
76.4% of cases. The most frequent reasons to 
decide against therapy were fear of side effects 
(38.2%) and lack of trust in efficacy (28.8%).
For 96.5% of patients on current MS therapy, 
doctors reported having the overall impression 
that the patients were adherent. Among working 
patients, the adherence rate was slightly higher 
(97.2%) compared with patients who were not 
employed (95.6%, p = 0.037). A total of 1326 of 
3312 patients (40.0%) reported that they discon-
tinued therapy or had missed an injection. As the 
general reasons and reason for the discontinua-
tion of therapy, ‘side effects in general’ (41.9% 
and 25.3%, respectively) and ‘problems at the 
injection site’ (33.1% and 15.2%, respectively) 
were most frequently reported.
Interruptions of MS therapy were noted to occur 
more than once a week in 5.7% of patients, once 
a week in 7.2%, about once a month in 18.0%, 
and about once in 3 months in 23.9% of patients 
(missing data in 11.7%).
Global treatment satisfaction and effectiveness
An overview for all TSQM scores by different 
DMTs can be found in Table 1.
The main difference in global treatment related 
satisfaction was lower values for patients having 
dropped their last DMT in comparison to cur-
rently treated patients independently of the spe-
cific current DMT (ANOVA: p < 0.001, Table 1). 
Therapeutic Advances in Neurological Disorders 9(4)
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The same result was present in the regression tree 
analysis of global satisfaction (n = 2935, Figure 1). 
Further, higher global satisfaction was associated 
with fewer relapses, longer duration of medication, 
the absence of a MDE, a lower EDSS score and 
the absence of side effects like pain and fatigue. 
These results could be confirmed by a comprehen-
sive ANCOVA for all predictors of the tree model 
(with all p values < 0.01) except fatigue.
In a similar set of analyses, the effectiveness 
score presented lowest ratings for the previously 
treated patients without current medication 
compared with all other patients (ANOVA: p < 
0.001). Also, GA showed a small significant 
difference (p = 0.045) compared with IFN β1a 
intramuscularly. In CRT analysis, fewer 
relapses were connected with higher effective-
ness (Figure 2). The type of medication (as sug-
gested by the ANOVA results), lower EDSS, sex 
(in favour of female patients), longer duration of 
medication, the absence of flu-like symptoms 
and pain also predicted better effectiveness rat-
ings. On a global level, the ANCOVA results 
confirm the extracted predictors except the two 
side effects on a 0.01% level.
Side effects and treatment convenience
Nearly half of the patients (42.8%) reported side 
effects, most commonly skin reactions at the 
injection site (24.9%) and influenza-like symp-
toms (23.6%), followed by pain at the injection 
site (13.9%). Concerning the degree of severity of 
the side effects, increased fatigue was most fre-
quently classified as moderate (49.0%), while the 
other side effects were predominantly assessed as 
mild. Being asked which application form they 
would prefer, 79.3% chose oral application, 
11.8% subcutaneous injection, 6.8% intramuscu-
lar injection and 2.1% infusion.
Most differences in TSQM scores between DMTs 
were found by analysing the side effects score. 
Only IFN β1a subcutaneously and IFN β1b sub-
cutaneously did not differ from each other in a 
statistically significant way (p = 0.067). All other 
paired comparisons were significant at least on a 
1% level (Table 1). Patients with GA reported 
fewer side effects than patients with other DMTs. 
For all IFN β DMTs, the presence of flu-like 
symptoms was the main predictor of a bad side 
effects score in CRTs (Figure 3). Subsequently, 
presence of pain, injection site reactions, head-
ache or fatigue was also associated with a decreased 
side effects score across the DMTs.
Looking at the results for convenience, IFN β1a 
intramuscularly, IFN β1b subcutaneously and 
GA received comparable ratings. Patients receiv-
ing IFN β1a subcutaneously reported higher con-
venience for their treatment (p < 0.01 versus IFN β1a intramuscularly and IFN β1b subcutane-
ously; p < 0.001 versus GA) whereas patients hav-
ing dropped their last DMT presented lower 
convenience score values (p < 0.001 versus IFNs, 
p = 0.016 versus GA). Predicting factors for treat-
ment convenience were dominated by potential 
side effects (Figure 4).
Facets of satisfaction
A linear regression analysis provided insights on 
the plain (nonhierarchical) connection between 
the components of the satisfaction with the 
global satisfaction score. The model fit (adjusted 
Table 1. Treatment satisfaction of different DMTs in patients with MS by TSQM.
TSQM scores No DMT IFN β1a 
intramuscularly
IFN β1a 
subcutaneously
IFN β1b 
subcutaneously
GA 
 n = 441 n = 704 n = 687 n = 564 n = 785
Mean SD Mean SD Mean SD Mean SD Mean SD
Global satisfaction* 47.7 31.32 72.3 20.36 72.3 19.74 72.6 21.03 71.4 20.48
Effectiveness* 50.9 26.51 70.0 22.65 68.1 22.39 67.6 23.48 66.5 22.90
Side effects* 60.9 37.19 67.7 27.09 73.4 26.85 77.6 25.53 83.9 23.65
Convenience* 63.8 27.40 70.2 21.72 74.2 20.11 70.1 20.70 68.8 19.51
*ANOVA result: p < 0.001.
DMT, disease-modifying treatment; GA, glatiramer acetate; IFN, interferon; SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire 
for Medication.
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R² = 0.493, p < 0.001) and the β coefficients 
(effectiveness: β = 0.421, p < 0.001; side effects: β = 0.218, p < 0.001; convenience: β = 0.294, 
p < 0.001) of the analysis provided further gen-
eral information about the relationship between 
facets of satisfaction in patients with MS.
In addition to the patient-generated TSQM 
scores, physicians rated adherence, overall side 
effects, overall convenience and overall satisfac-
tion with the current medication. An overview of 
rank correlation coefficients between those 
parameters is given in Table 2. Physicians’ rating 
of patients’ adherence showed small but still 
highly significant correlations with other physi-
cian ratings and TSQM scores. Focusing on phy-
sicians’ ratings, convenience turned out to be the 
parameter with the highest correlations.
With respect to adherence, higher correlations 
were found for convenience and satisfaction than 
for side effects (Table 2). Strongest associations 
between physicians and patients were found for 
the same domains (e.g. side effects rated by physi-
cians with side effects of TSQM) supporting the 
validity of the given results. Again, the relationship 
Figure 1. Regression tree analysis of global satisfaction (TSQM, N = 2935). DMD, disease-modifying drug; 
EDSS, Expanded Disability Status Scale; IFN, interferon; i.m., intramuscular; s.c., subcutaneous; TSQM, 
Treatment Satisfaction Questionnaire for Medication.
T
h
e
ra
p
e
u
tic A
d
va
n
ce
s in
 N
e
u
ro
lo
g
ica
l D
iso
rd
e
rs 9
(4
)
2
5
6
 
h
ttp
://ta
n
.sa
g
e
p
u
b
.co
m
Figure 2. Regression tree analysis of effectiveness (TSQM, N = 2952). DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; IFN, interferon; i.m., 
intramuscular; s.c., subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.
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Figure 3. Regression tree analyses of side effects (TSQM, N = 2680). GA, glatiramer acetate; IFN, interferon; i.m., intramuscular; MS, multiple sclerosis; s.c., 
subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.
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Figure 4. Regression tree analyses of convenience (TSQM, N = 2708). IFN, interferon; GA, glatiramer acetate; i.m., intramuscular; s.c., subcutaneous; TSQM, 
Treatment Satisfaction Questionnaire for Medication.
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between TSQM scores was described by correla-
tional coefficients matching with the results of the 
linear regression model.
Discussion
In the present observational study, we surveyed 
patients with MS treated by first-line injectable 
treatment (as specified in the DGN guideline) 
[DGN/KKNMS, 2012] about their general and 
specific treatment satisfaction.
We were able to collect a comprehensive dataset 
providing standardized information about several 
aspects of treatment satisfaction and adherence 
for the injectable MS treatments at the time of the 
start of the survey. We showed that global treat-
ment satisfaction and perceived effectiveness did 
not differ in general between DMTs. Scores of 
side effects and convenience varied between 
DMTs depending on their type of application 
and pharmaceutical ingredient. For all facets of 
satisfaction, we identified predictors and were 
able to validate patient-reported values against 
physicians’ ratings.
Treatment satisfaction
The importance of the patient’s perspective on 
treatments for various indications including MS 
has been highlighted in recent years [US 
Department of Health and Human Services FDA 
Center for Drug Evaluation and Research, 2006; 
Coons et  al. 2009; Rieckmann et  al. 2015]. 
However, the majority of studies focused on qual-
ity of life and adherence or persistence of therapy, 
while patient satisfaction with treatment has only 
been assessed in a few specific studies. We chose 
the TSQM as an established generic instrument 
for the assessment of patient satisfaction, which 
has been validated in several chronic indications 
including MS and which is available in several lan-
guages including German [Atkinson et al. 2004].
Besides general reference values for patients in a 
mostly stable treatment environment, we 
extracted patterns of satisfaction with data-driven 
regression tree analyses. According to our results, 
patients’ opinion about the effectiveness and the 
closely related overall satisfaction is built upon 
their experience with the current DMT. A 
relapse-free treatment was the best predictor for 
high ratings, followed by a progression-free treat-
ment and the absence of further side effects like 
pain, fatigue and depression symptoms. The deci-
sion about a successful treatment course or the 
need for a change of DMT may mostly be made 
between 1 and 5 years of treatment, which was 
indicated by the positive association of short-term 
and long-term treatment duration with higher 
satisfaction compared with mid-term durations. 
Such patterns may become important when 
healthcare professionals have to address treat-
ment expectations, improve communication with 
the patient, and manage side effects of treatment 
[Brandes et al. 2009].
Satisfaction of patients treated with conventional 
DMTs has been reported in several current stud-
ies, in which, however, ratings on TSQM varied 
substantially: in a study of 568 patients who 
applied a new device for subcutaneous self 
Table 2. Correlational analyses of satisfaction, side effects, convenience and adherence between patients’ and physicians’ ratings.
Physician: 
ADHER
Physician: 
SE
Physician: 
CONV
Physician: 
SAT
Patient: 
TSQM EFF
Patient: 
TSQM SE
Patient: TSQM 
CONV
Physician: ADHER –  
Physician: SE −0.116* –  
Physician: CON −0.164* 0.372* –  
Physician: SAT −0.145* 0.370* 0.579* –  
Patient: TSQM EFF −0.067* 0.146* 0.216* 0.282* –  
Patient: TSQM SE −0.058* 0.321* 0.201* 0.219* 0.227* –  
Patient: TSQM CON −0.089* 0.130* 0.293* 0.235* 0.264* 0.254* –
Patient: TSQM GS −0.092* 0.157* 0.247* 0.335* 0.508* 0.288* 0.392*
*Kendall τ-b: p < 0.001.
ADHER, adherence (no/yes); CONV, convenience; EFF, effectiveness; GS, global satisfaction; Patient, rating by patient (via TSQM); Physician, rating 
by physician; SAT, satisfaction; SE, side effects; TSQM, Treatment Satisfaction Questionnaire for Medication.
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injection of IFN β1b, on TSQM effectiveness at 
12 weeks was rated at 49.7 (±18.6) points, con-
venience at 55.0 (±16.1) and global satisfaction 
at 47.3 (±19.6), while the side-effect subscale 
was not reported [Boeru et al. 2013].
Various first-line therapies were jointly assessed 
in the Spanish COMPLIANCE study (subcuta-
neous IFN β1b in 23%, intramuscular IFN β1a in 
21%, subcutaneous IFN β1a in 37% and GA in 
19%) [Saiz et al. 2015].
The mean score for effectiveness was 64.0 
(±20.8), for side effects 63.4 (±22.0), for con-
venience 60.2 (±19.2) and for global satisfaction 
69.8 (±10.2). On all scales, compliant patients 
had higher scores compared with noncompliant 
patients. Further, in the controlled TENERE 
study [ClinicalTrials.gov identifier: NCT00883337], 
in 101 patients on subcutaneous IFN β1a, effec-
tiveness was rated at 59.3, for side effects 71.4, 
for convenience 61.9 and for global satisfaction 
61.0 [Vermersch et al. 2014]. Compared with the 
conventional injectable therapies, the novel oral 
MS therapies achieved substantially higher satis-
faction on TSQM: in the TENERE study, for 
teriflunomide, all scores were substantially higher 
(depending on the dose) with effectiveness rated 
at 63–67 points, side effects at 93–95 points, con-
venience at 88–90 points and global satisfaction 
at 68–69 points. Our values of satisfaction and 
effectiveness were slightly higher than those 
reported in the cited studies, which may be a 
result of the broad and noninterventional charac-
ter of the study where a stable treatment situation 
may be likely assumed.
In a cross-sectional survey with 310 patients on 
fingolimod, TSQM scores were highest for side 
effects (79.4), followed by convenience (71.7), 
effectiveness (70.1) and global satisfaction 
(68.9); relatively higher scores were observed 
among treatment-experienced patients [Hanson 
et al. 2013].
In the publication on the EPOC study which com-
pared the switch from GA or beta interferons to 
fingolimod versus staying on the injectable 
DMT, no absolute TSQM values were reported 
[Calkwood et  al. 2014]. However, patients 
switched to oral therapy improved on the effec-
tiveness scale depending on the original injectable 
DMT by 12–18 points, on the side effects scale 
by 9–31 points and on the convenience scale by 
38–44 points (values for global satisfaction were 
not given).
Treatment adherence
It is well known that physicians’ and patients’ 
views on various aspects of a disease may vary. 
For example, Rothwell and colleagues showed 
that patients with MS and possibly those with 
other chronic diseases are less concerned than 
their clinicians about physical disability in their 
illness [Rothwell et al. 1997].
Assessment and perception of therapeutic risks 
vary among patients, doctors and regulators 
[Clanet et al. 2014].
It has been reported in several studies that adher-
ent patients report greater satisfaction with DMT 
with regard to convenience and effectiveness 
[Twork et al. 2007; Treadaway et al. 2009; Saiz 
et al. 2015].
It was interesting to note that physicians in our 
study had the impression that 96.5% of patients 
receiving therapy were adherent to treatment, 
which was clearly above the expected level. 
However, at least a quarter of patients missed 
doses during the last 3 months. This is in line 
with the large Global Adherence Project, in which 
patients with RRMS reported nonadherence or 
missing DMT injections in the previous month in 
25%, most frequently due to forgetfulness or 
injection-related reasons [Devonshire et al. 2011].
Several other studies confirm lower adherence 
rates in MS. In a systematic review of 24 studies 
published between 2001 and 2011, Menzin and 
colleagues reported adherence rates in patients 
with MS ranging from 41% to 88% [Menzin et al. 
2013]. Like Halpern and colleagues, they found 
higher weighted mean adherence rates for intra-
muscular IFN β1a administered once a week 
(69.4%), and subcutaneous IFN β1a adminis-
tered every other day (63.8%) than for subcuta-
neous IFN β1b administered three times a week 
(58.4%) and GA administered daily (56.8%) 
[Halpern et al. 2011]. Further, there was a numer-
ically greater risk of MS relapse or disease pro-
gression among nonadherent patients compared 
with those categorized as adherent patients, with 
findings statistically significant in two out of four 
analysed studies. Hansen and colleagues also exe-
cuted a data-driven approach to research patient 
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adherence in MS by evaluating German claims 
data between 2001 and 2009 and finding only 
30–40% of patients to be adherent to treatment 
over a period of 2 years [Hansen et  al. 2015]. 
Agashivala and colleagues showed in another ret-
rospective study on adherence to MS DMTs in 
2013 that higher adherence rates were seen in an 
oral DMT compared with self-injection DMTs 
[Agashivala et al. 2013].
Limitations
When interpreting the results of the present study, 
some further methodological considerations need 
to be taken into account. The study used an 
observational design, which may lead to unknown 
bias in the selection of patients with MS (i.e. 
underrepresentation of critically ill individuals) 
[Delgado-Rodriguez and Llorca, 2004]. No 
explicit exclusion criteria for documentation were 
stated to avoid selection bias.
Further, neurologists willing to participate in the 
survey may be a positive selection of physicians 
with a particular interest and knowledge in the 
field of MS management. Adherent patients are 
more likely to provide their informed consent for 
study participation [Van Onzenoort et al. 2011].
The unusual high adherence rate may result from 
the fact that assessment of adherence was reduced 
to a single item for physicians and, therefore, may 
have limited the precision of the adherence esti-
mation. The majority of the included patients 
(92.3%) presented an EDSS below or equal to 
5.5, limiting the generalizability of the results for 
patients with severe disabilities. Additional non-
MS-specific medications were not included in the 
survey. Accordingly, there was no further infor-
mation available about the symptomatic treatment 
of side effects like nonsteroidal anti-inflammatory 
medication for flu-like symptoms and their poten-
tial influence on adherence and satisfaction.
Among the strengths of the study is its large scale, 
with complete coverage of all regions in Germany, 
and strong focus on the ambulatory setting rather 
than on university or specialist centres. Our study 
was not designed to assess medication effects.
Conclusion
On the road to adherence, we have to overcome 
several obstacles. In a connected model of patient’s 
satisfaction, perceived effectiveness, side effects, 
convenience and adherence, patients’ individual 
needs and concerns have to be addressed. In this 
study, several factors were identified to play an 
important role in patients’ perception of their 
treatment, and therefore, are likely to mediate or 
moderate their adherence to the current treat-
ment. Most differences were found with respect to 
side effects and convenience of treatment. 
Therefore, an improvement in these two domains 
seems to be the most promising proximate 
approach to elevate adherence levels. Quality 
information by the physician on the strengths and 
weaknesses of different treatments is also a neces-
sary step to create realistic expectations which will 
form the basis for treatment satisfaction. 
Decreased disease activity and consequently 
higher quality of life as a result of long-term ther-
apy with increased adherence may be bound to 
orally administered therapies, as they represent a 
highly promising way to more convenience and 
fewer application-related side effects.
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